329 related articles for article (PubMed ID: 21905952)
1. Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin's lymphoma patients treated with immunochemotherapy.
Nosotti L; D'Andrea M; Pitidis A; Pimpinelli F; Dessanti ML; Pisani F; Vignally P; Petti MC
Scand J Infect Dis; 2012 Jan; 44(1):70-3. PubMed ID: 21905952
[TBL] [Abstract][Full Text] [Related]
2. HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens.
Marignani M; Mangone M; Cox MC; Angeletti S; Veggia B; Ferrari A; di Fonzo M; Begini P; Gigante E; Laverde G; Aloe-Spiriti A; Monarca B; Delle Fave G
Dig Liver Dis; 2011 Feb; 43(2):139-42. PubMed ID: 20554488
[TBL] [Abstract][Full Text] [Related]
3. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy.
Ennishi D; Terui Y; Yokoyama M; Mishima Y; Takahashi S; Takeuchi K; Okamoto H; Tanimoto M; Hatake K
Am J Hematol; 2008 Jan; 83(1):59-62. PubMed ID: 17712791
[TBL] [Abstract][Full Text] [Related]
4. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma.
Faggioli P; De Paschale M; Tocci A; Luoni M; Fava S; De Paoli A; Tosi A; Cassi E
Haematologica; 1997; 82(1):38-42. PubMed ID: 9107080
[TBL] [Abstract][Full Text] [Related]
5. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
[TBL] [Abstract][Full Text] [Related]
6. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
7. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.
Pei SN; Ma MC; Wang MC; Kuo CY; Rau KM; Su CY; Chen CH
Ann Hematol; 2012 Jul; 91(7):1007-12. PubMed ID: 22273839
[TBL] [Abstract][Full Text] [Related]
8. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
10. Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C.
Dizdar O; Tapan U; Aksoy S; Harputluoglu H; Kilickap S; Barista I
Eur J Haematol; 2008 May; 80(5):381-5. PubMed ID: 18221389
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study.
Hsu C; Tsou HH; Lin SJ; Wang MC; Yao M; Hwang WL; Kao WY; Chiu CF; Lin SF; Lin J; Chang CS; Tien HF; Liu TW; Chen PJ; Cheng AL;
Hepatology; 2014 Jun; 59(6):2092-100. PubMed ID: 24002804
[TBL] [Abstract][Full Text] [Related]
12. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study.
Bianco E; Marcucci F; Mele A; Musto P; Cotichini R; Sanpaolo MG; Iannitto E; De Renzo A; Martino B; Specchia G; Montanaro M; Barbui AM; Nieddu R; Pagano L; Rapicetta M; Franceschi S; Mandelli F; Pulsoni A;
Haematologica; 2004 Jan; 89(1):70-6. PubMed ID: 14754608
[TBL] [Abstract][Full Text] [Related]
15. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies.
Zuckerman E; Zuckerman T; Douer D; Qian D; Levine AM
Cancer; 1998 Sep; 83(6):1224-30. PubMed ID: 9740089
[TBL] [Abstract][Full Text] [Related]
16. Rituximab tolerability when given before or after CHOP.
Hannawa IS; Bestul DJ
J Oncol Pharm Pract; 2011 Dec; 17(4):381-6. PubMed ID: 21109616
[TBL] [Abstract][Full Text] [Related]
17. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].
Mimura N; Tsujimura H; Ise M; Sakai C; Kojima H; Fukai K; Yokosuka O; Takagi T; Kumagai K
Rinsho Ketsueki; 2009 Dec; 50(12):1715-9. PubMed ID: 20068280
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin's lymphoma in Korea.
Park SC; Jeong SH; Kim J; Han CJ; Kim YC; Choi KS; Cho JH; Lee M; Jung HH; Ki SS; Chang YH; Lee SS; Park YH; Lee KH
J Med Virol; 2008 Jun; 80(6):960-6. PubMed ID: 18428141
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs.
Besson C; Canioni D; Lepage E; Pol S; Morel P; Lederlin P; Van Hoof A; Tilly H; Gaulard P; Coiffier B; Gisselbrecht C; Brousse N; Reyes F; Hermine O;
J Clin Oncol; 2006 Feb; 24(6):953-60. PubMed ID: 16418500
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results.
Tobinai K; Ogura M; Itoh K; Kinoshita T; Hotta T; Watanabe T; Morishima Y; Igarashi T; Terauchi T; Ohashi Y;
Cancer Sci; 2010 Dec; 101(12):2579-85. PubMed ID: 20942866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
